Literature DB >> 14726391

Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes.

Pearlie Kay Epling-Burnette1, Jeffrey S Painter, Pratima Chaurasia, Fanqi Bai, Sheng Wei, Julie Y Djeu, Thomas P Loughran.   

Abstract

The natural killer (NK) type of lymphoproliferative disease of granular lymphocytes (LDGL) is associated with the expansion of CD3(-), CD16(+), and/or CD56(+) lymphocytes. We have examined the repertoire of NK receptors expressed on these cells and delineated the functional activity. We found skewed NK receptor expression on patient NK cells. Reactivity to a single anti-killer cell immunoglobulin-like receptor (anti-KIR) antibody was noted in 7 of 13 patients. LDGL patients variably expressed NKp30, NKp44, and NKp46 RNA. In contrast, CD94 and its inhibitory heterodimerization partner NKG2A were homogeneously expressed at high levels on these NK cells. Interestingly, these patients expressed a large number of activating KIR receptors by genotype analysis. Semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) demonstrated that lower than normal levels of RNA of the inhibitory KIR was present in some patients in contrast to normal NK cells. Consistent with a high level of activating receptors, we found the NK-LDGL cells have potent cytolytic function in both direct and redirected cytotoxicity assays. These results demonstrate that patients with NK-LDGL have an increased activating-to-inhibitory KIR ratio. This altered ratio might induce inappropriate lysis or cytokine production and impact the disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726391     DOI: 10.1182/blood-2003-02-0400

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

2.  Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia.

Authors:  Adam W Mailloux; Ling Zhang; Lynn Moscinski; John M Bennett; Lili Yang; Sean J Yoder; Gregory Bloom; Cody Wei; Sheng Wei; Lubomir Sokol; Thomas P Loughran; Pearlie K Epling-Burnette
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

3.  Distribution of several activating and inhibitory receptors on CD3-CD16+ NK cells and their correlation with NK cell function in healthy individuals.

Authors:  Gordana Konjević; Katarina Mirjacić Martinović; Ana Vuletić; Vladimir Jurisić; Ivan Spuzić
Journal:  J Membr Biol       Date:  2009-08-27       Impact factor: 1.843

4.  Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches.

Authors:  Renato Zambello; Gianpietro Semenzato
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

Review 5.  The pathogenesis and treatment of large granular lymphocyte leukemia.

Authors:  Steven Nathaniel Steinway; Francis LeBlanc; Thomas P Loughran
Journal:  Blood Rev       Date:  2014-03-07       Impact factor: 8.250

6.  Target and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling.

Authors:  Anna H C Vlot; Wilhelmus E A de Witte; Meindert Danhof; Piet H van der Graaf; Gerard J P van Westen; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

7.  Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients.

Authors:  E Poullot; R Zambello; F Leblanc; B Bareau; E De March; M Roussel; M L Boulland; R Houot; A Renault; T Fest; G Semenzato; T Loughran; T Lamy
Journal:  Ann Oncol       Date:  2014-08-05       Impact factor: 32.976

8.  Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway.

Authors:  Jun Yang; Xin Liu; Susan B Nyland; Ranran Zhang; Lindsay K Ryland; Kathleen Broeg; Kendall Thomas Baab; Nancy Ruth Jarbadan; Rosalyn Irby; Thomas P Loughran
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  The human androgen receptor X-chromosome inactivation assay for clonality diagnostics of natural killer cell proliferations.

Authors:  Michaël Boudewijns; Jacques J M van Dongen; Anton W Langerak
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

10.  Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling.

Authors:  P K Epling-Burnette; Lubomir Sokol; Xianhong Chen; Fanqi Bai; Junmin Zhou; Michelle A Blaskovich; JianXiang Zou; Jeffrey S Painter; Todd D Edwards; Lynn Moscinski; Jeffrey A Yoder; Julie Y Djeu; Said Sebti; Thomas P Loughran; Sheng Wei
Journal:  Blood       Date:  2008-09-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.